Please disable Ad Blocker before you can visit the website !!!

Ensysce Biosciences Long

by SignalFactory   ·  December 9, 2021 | 11:24:19 UTC  

Ensysce Biosciences Long

by SignalFactory   ·  December 9, 2021 | 11:24:19 UTC  

Ensysce Biosciences, Inc. is a clinical-stage biotechnology firm that uses its proprietary technology to produce safer prescription drugs. The company is currently developing a new type of tamper-proof opioids that control overdoses and drug abuse.

On 30th November 2021, ENSC reported the completion of safety review and enrollment of the last cohort of subjects in its study of Trypsin Activated Abuse Protected Opioid. The PF614-102 is a randomized, phase 1b, single-center clinical study. The study evaluates the bioavailability of single oral doses of PF614 and the safety of multiple-ascending oral doses of PF614 relative to OxyContin.

Mr. Matthew Johnston, PRA Health Sciences, is directing the study. After receiving a favorable safety review from the Safety Review Committee, the company has advanced the trial to a higher dose level. ENSC anticipates entering the bioequivalence stage of the study by January 2022. The data from the MAD study has expected to release by the first quarter of 2022.

ENSC Third Quarter 2021 Financial Results –
On 15th November 2021, ENSC published its financial results for the third quarter of 2021. The company has also presented its current business updates.

Financial Highlights:
As of 30th September 2021, ENSC has $6.8 million in cash and cash equivalents. Net loss was $17.2 million for three months ended 30th September 2021. For the third quarter of 2020, ENSC has $1.6 million in net income. Research and development costs totaled $1.7 million for the third quarter ended 30th September 2021. For the same three months of 2020, research and development expenses were $0.9 million. The company reported general and administrative costs of $16.4 million for the third quarter of 2021. General and administrative expenses were $0.3 million for the previous year’s third quarter.

Management Comments:
Chief executive officer of ENSC, Dr. Lynn Kirkpatrick, remarked that they had successfully achieved convertible note financing of $15M during the third quarter. It has provided them with the required proceeds to advance their leading clinical trials. They have already started the second study of TAAP opioids in September 2021, he added.

Ensysce Biosciences Long (Buy)
Enter At: 3.14
T.P_1: 4.10
T.P_2: 4.91
T.P_3: 5.58
S.L: 2.19

Ensysce Biosciences Inc.
Ensysce Biosciences Inc.
All information on this website is of a general nature. The information is not adapted to conditions that are specific to your person or entity. The information provided can not be considered as personal, professional or legal advice or investment advice to the user. This website and all information is intended for educational purposes only and does not give financial advice. Signal Factory is not a service to provide legal and financial advice; any information provided here is only the personal opinion of the author (not advice or financial advice in any sense, and in the sense of any act, ordinance or law of any country) and must not be used for financial activities. Signal Factory does not offer, operate or provide financial, brokerage, commercial or investment services and is not a financial advisor. Rather, Signal Factory is an educational site and a platform for exchanging Forex information. Whenever information is disclosed, whether express or implied, about profit or revenue, it is not a guarantee. No method or trading system ensures that it will generate a profit, so always remember that trade can lead to a loss. Trading responsibility, whether resulting in profits or losses, is yours and you must agree not to hold Signal Factory or other information providers that are responsible in any way whatsoever. The use of the system means that the user accepts Disclaimer and Terms of Use. Signal Factory is not represented as a registered investment consultant or brokerage dealer nor offers to buy or sell any of the financial instruments mentioned in the service offered. While Signal Factory believes that the content provided is accurate, there are no explicit or implied warranties of accuracy. The information provided is believed to be reliable; Signal Factory does not guarantee the accuracy or completeness of the information provided. Third parties refer to Signal Factory to provide technology and information if a third party fails, and then there is a risk that the information may be delayed or not delivered at all. All information and comments contained on this website, including but not limited to, opinions, analyzes, news, prices, research, and general, do not constitute investment advice or an invitation to buy or sell any type of instrument. Signal Factory assumes no responsibility for any loss or damage that may result, directly or indirectly, from the use or dependence on such information. All information contained on this web site is a personal opinion or belief of the author. None of these data is a recommendation or financial advice in any sense, also within the meaning of any commercial act or law. Writers, publishers and affiliates of Signal Factory are not responsible for your trading in any way. The information and opinions contained in the site are provided for information only and for educational reasons, should never be considered as direct or indirect advice to open a trading account and / or invest money in Forex trading with any Forex company . Signal Factory assumes no responsibility for any decisions taken by the user to create a merchant account with any of the brokers listed on this website. Anyone who decides to set up a merchant account or use the services, free of charge or paid, to any of the Forex companies mentioned on this website, bears full responsibility for their actions. Any institution that offers a service and is listed on this website, including forex brokers, financial companies and other institutions, is present only for informational purposes. All ratings, ratings, banners, reviews, or other information found for any of the above-mentioned institutions are provided in a strictly objective manner and according to the best possible reflection of the materials on the official website of the company. Forex trading is potentially high risk and may not be suitable for all investors. The high level of leverage can work both for and against merchants. Before each Forex investment, you should carefully consider your goals, past experience and risk level. The opinions and data contained on this site should not be considered as suggestions or advice for the sale or purchase of currency or other instruments. Past results do not show or guarantee future results. Neither Signal Factory nor its affiliates ensure the accuracy of the content provided on this Site. You explicitly agree that viewing, visiting or using this website is at your own risk.

Signal Factory is now on Telegram

make sure to join our Telegram channel now and you will not miss any update